Effect of Cytomodulin-10 (TGF-beta1 analogue) on wound healing by primary intention in a murine model.
OBJECTIVE
To evaluate the effect of Cytomodulin-10 (CM-10), a transforming growth factor-beta analogue, on wound healing by primary intention.


METHODS
Sixty male albino rats of Charles Foster strain (100-150 g) were used. After intraperitoneal anesthesia, a cutaneous incised wound (4 cm) was created on the back of each rat, which was closed by silk stitches and allowed to heal by primary intention. They were equally divided as test and control. CM-10 was applied to the test wounds daily. At the end of 7, 14 and 21 days of wounding, 10 rats from each group were sacrificed and their wounds were compared. Outcome measures were: 1) breaking force of wounds, 2) histological assessment of healing and 3) evaluation of angiogenesis. Statistical significance was assessed by Student's t-test, ANOVA and Bonferroni correction.


RESULTS
There was a significant increase in the breaking force (P<0.001). Histological examination showed early epithelization, increased collagen deposition and decreased inflammatory cellular infiltrate at 1st week in the test group. The treated wounds also demonstrated earlier remodeling. Angiogenesis score was significantly higher in the test wounds at 1st week (40.6 vs. 30.8; P<0.001), but not in the subsequent weeks.


CONCLUSIONS
Cytomodulin is a strong promoter of wound healing by primary intention. It increases tensile strength and induces early epithelization. It also promotes increased collagen deposition, early remodeling and increased angiogenesis.
Basu
Somprakas
S
Department of General Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India. sombasu@hotmail.com
Kumar
Mohan
M
Chansuria
J P N
JP
Singh
Tej Bali
TB
Bhatnagar
Raj
R
Shukla
Vijay K
VK
D000287:Administration, Topical; D000818:Animals; D004195:Disease Models, Animal; D008297:Male; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D012867:Skin / Q000098:blood supply / Q000293:injuries* / Q000473:pathology; D053773:Transforming Growth Factor beta1; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000188:drug therapy* / Q000473:pathology
D009842:Oligopeptides; D053773:Transforming Growth Factor beta1